Natera (NASDAQ:NTRA) Stock: Insider John Fesko Sells 781 Shares

Posted by Francis Steltz on Oct 29th, 2026

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider John Fesko sold 781 shares of the company’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00. Following the completion of the transaction, the insider owned 196,476 shares in the company, valued at approximately $79,769,256. The trade was a 0.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $382,853.32.
On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01.
On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05.

Natera Trading Up 2.7%

Shares of NASDAQ NTRA traded up $11.58 during midday trading on Thursday, hitting $436.00. The stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. The business’s 50 day moving average is $375.27 and its 200-day moving average is $265.54. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) earnings per share. On average, equities research analysts expect that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Rothschild & Co Redburn started coverage on shares of Natera in a research report on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective on the stock. Robert W. Baird set a $348.00 target price on shares of Natera in a research note on Friday, August 7th. Stephens raised their price target on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Guggenheim lifted their price objective on Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, TD Cowen upped their price objective on Natera from $340.00 to $480.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Get Our Latest Stock Report on NTRA

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Greenleaf Trust purchased a new stake in Natera in the 3rd quarter worth approximately $240,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Natera during the third quarter valued at approximately $7,545,000. Profund Advisors LLC lifted its holdings in Natera by 5.6% during the third quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company’s stock valued at $2,708,000 after purchasing an additional 348 shares in the last quarter. Vise Technologies Inc. lifted its holdings in Natera by 5.3% during the third quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company’s stock valued at $831,000 after purchasing an additional 101 shares in the last quarter. Finally, Americana Partners LLC bought a new position in shares of Natera in the third quarter worth approximately $203,000. Institutional investors own 99.90% of the company’s stock.

Natera News Roundup

Here are the key news stories impacting Natera this week:

Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Natera Company Profile

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.